Table 3.
Mean (% CV) for DFRF4539A pharmacokinetic parameters—including total antibody, antibody-conjugated mono methyl auristatin E (ac-MMAE), and unconjugated MMAE analytes—in cycle 1 at 2.4 mg/kg
| Dose (mg/kg) |
C
max
Mean (%CV) |
AUCinf Mean (%CV) |
CL Mean (%CV) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Ab (μg/mL) | ac-MMAE (ng/mL) | Unconjugated MMAE (ng/mL) |
Total Ab (μg/mL) | ac-MMAE (ng/mL) | Unconjugated MMAE (ng/mL) |
Total Ab (μg/mL) | ac-MMAE (ng/mL) | Unconjugated MMAE (ng/mL) |
|
| 2.4 Q3W (n = 16) |
55.1 (32%) |
876 (49%) |
3.14 (45%) |
291 (35%) |
2660 (33%) |
35.2 (54%) |
9.6 (44%) |
17.6 (37%) |
NA |
AUCinf area under the concentration-time profile extrapolating to time of infinity, Cmax maximum concentration, CL clearance, acMMAE monomethyl auristatin E, NA not available